4D Molecular Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
196
- Stock Symbol
-
FDMT
- Investments
-
1
- Share Price
-
$12.21
- (As of Friday Closing)
4D Molecular Therapeutics General Information
Description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Contact Information
Website
www.4dmoleculartherapeutics.comCorporate Office
- 5858 Horton Street
- Suite 455
- Emeryville, CA 94608
- United States
Corporate Office
- 5858 Horton Street
- Suite 455
- Emeryville, CA 94608
- United States
4D Molecular Therapeutics Stock Performance
As of 13-Nov-2026, 4D Molecular Therapeutics’s stock price is $12.21. Its current market cap is $690M with 56.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.21 | $12.12 | $6.96 - $16.93 | $690M | 56.4M | 1.06M | -$2.70 |
4D Molecular Therapeutics Financials Summary
As of 30-Sep-2026, 4D Molecular Therapeutics has a trailing 12-month revenue of $96.1M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 468,428 | 145,713 | (219,570) | 561,681 |
| Revenue | 96,064 | 85,209 | 37 | 20,723 |
| EBITDA | (209,991) | (151,959) | (181,213) | (107,299) |
| Net Income | (200,354) | (140,109) | (160,868) | (100,837) |
| Total Assets | 428,749 | 566,711 | 560,384 | 339,891 |
| Total Debt | 38,413 | 21,413 | 24,606 | 14,671 |
4D Molecular Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
4D Molecular Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
4D Molecular Therapeutics Comparisons
Industry
Financing
Details
4D Molecular Therapeutics Competitors (46)
One of 4D Molecular Therapeutics’s 46 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Kodiak Sciences | Formerly VC-backed | Palo Alto, CA |
4D Molecular Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
4D Molecular Therapeutics Patents
4D Molecular Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178040-A1 | Compositions and methods for selective gene expression in the treatment of ocular disease | Pending | 18-Feb-2025 | ||
| WO-2026072591-A1 | Combination therapy with adeno-associated virus and cftr modulator(s) for treatmet of cftr | Pending | 25-Sep-2024 | ||
| WO-2026019840-A1 | Methods for treating diabetic macular edema with adeno-associated virus | Pending | 16-Jul-2024 | ||
| WO-2026019797-A1 | Methods for treating wet age-related macular degeneration with adeno-associated virus | Pending | 16-Jul-2024 | ||
| WO-2025255268-A1 | Dosing regimens and formulations for adeno-associated virus delivery of cftr | Pending | 05-Jun-2024 | C07K14/4712 |
4D Molecular Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
4D Molecular Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
4D Molecular Therapeutics Investments (1)
4D Molecular Therapeutics’s most recent deal was a Corporate Asset Purchase with Aevitas Therapeutics (Short-Form Human Complement Factor H). The deal was made on 24-Apr-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aevitas Therapeutics (Short-Form Human Complement Factor H) | 24-Apr-2023 | Corporate Asset Purchase | Buildings and Property |
4D Molecular Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
4D Molecular Therapeutics FAQs
-
When was 4D Molecular Therapeutics founded?
4D Molecular Therapeutics was founded in 2013.
-
Where is 4D Molecular Therapeutics headquartered?
4D Molecular Therapeutics is headquartered in Emeryville, CA.
-
What is the size of 4D Molecular Therapeutics?
4D Molecular Therapeutics has 196 total employees.
-
What industry is 4D Molecular Therapeutics in?
4D Molecular Therapeutics’s primary industry is Drug Discovery.
-
Is 4D Molecular Therapeutics a private or public company?
4D Molecular Therapeutics is a Public company.
-
What is 4D Molecular Therapeutics’s stock symbol?
The ticker symbol for 4D Molecular Therapeutics is FDMT.
-
What is the current stock price of 4D Molecular Therapeutics?
As of 13-Nov-2026 the stock price of 4D Molecular Therapeutics is $12.21.
-
What is the current market cap of 4D Molecular Therapeutics?
The current market capitalization of 4D Molecular Therapeutics is $690M.
-
What is 4D Molecular Therapeutics’s current revenue?
The trailing twelve month revenue for 4D Molecular Therapeutics is $96.1M.
-
Who are 4D Molecular Therapeutics’s competitors?
Genetix Biotherapeutics, Caribou Biosciences, Gilead, Alnylam Pharmaceuticals, and Kodiak Sciences are some of the 46 competitors of 4D Molecular Therapeutics.
-
What is 4D Molecular Therapeutics’s annual earnings per share (EPS)?
4D Molecular Therapeutics’s EPS for 12 months was -$2.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
